Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3554

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Dialysis-Dependent Chronic Kidney Disease

Interventions

DRUG: Vadadustat
DRUG: Darbepoetin alfa

Sponsor

Akebia Therapeutics